screening

Researchers identify 72 novel genetic variants associated with breast cancer risk.

Using the mutagenic chemical N-ethyl-N-nitrosourea, researchers confirm the role of a gene in a piglet deformity and identify potential models for human diseases. 

Tests so far typically screen for risky patterns that may augment traditional types of clinical data.

A recent CRISPR study contradicted years of RNA interference research on a well-studied cancer drug target. But is it the last nail in the coffin for RNAi as a screening tool? 

HR 1313 could circumvent protections offered by the Genetic Information Nondiscrimination Act, enabling employers to incentivize employee sharing of genetic and other medical information.

Two independent groups demonstrate the utility of CRISPR-based techniques to identify regulatory elements that govern disease-linked genes. 

Researchers use the genome-editing tool to mutate binding pockets and identify potential anti-cancer drug targets.

Researchers hope to repurpose already-approved drugs into potential anti-Ebola therapies.

Improved methods to grow patients’ tumor cells in a dish offer opportunities to find durable therapies.

The cholesterol-lowering drugs could be used to treat people with two types of dwarfism, a study suggests.

Researchers are getting closer to detecting abnormal tumor DNA circulating in the bloodstream.

An expert panel finds that the benefits of breast cancer screening outweigh risks that the procedure will lead to unnecessary treatments.

A cheap pain reliever that can kill drug-resistant, tuberculosis-causing bacteria may never be tested.

US Preventive Services Task Force recommends against a commonly used prostate cancer screening.